Personalis
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our ultrasensitive assays combine tumor and normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultracomprehensive genomic profiling, and enhance biomarker strategy for drug development.
